Prolonged Clinical Follow-up of OPTIMA-5

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT05649696

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05649696
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05649696. Randomized; triple masking; primary purpose treatment. Start 2021-10-29 (actual); primary completion 2023-09-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prolonged Clinical Follow-up of OPTIMA-5
Condition
ST-segment Elevation Myocardial Infarction (STEMI)
Intervention (Drug)
Recombinant Staphylokinase
Intervention (Drug)
Normal Saline
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct05649696
Content hash
651e444b6e0c7c6255560b1574df3be86776a9b7dbef825b81bb6997a3ce8bf1